We present the case history of 2 patients with low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolemia who did not receive lipoprotein apheresis. We describe the subsequent effect of all lipid-lowering medications during their life course including resins, statins, ezetimibe, nicotinic acid/laropiprant, mipomersen, and lomitapide. These cases tell the story of siblings affected with this rare disease, who are free of symptoms but still are at a very high cardiovascular disease risk, and their treatment from childhood.

, , , ,
doi.org/10.1016/j.jacl.2017.01.004, hdl.handle.net/1765/97718
Journal of Clinical Lipidology
Department of Pharmacology

Yahya, R., Mulder, M., Sijbrands, E., Williams, M., & Roeters van Lennep, J. (2017). Low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid-lowering therapy. Journal of Clinical Lipidology, 11(1), 301–305. doi:10.1016/j.jacl.2017.01.004